Protease inhibitors enhance levodopa effects in Parkinson's disease
Identifieur interne : 000A06 ( Istex/Corpus ); précédent : 000A05; suivant : 000A07Protease inhibitors enhance levodopa effects in Parkinson's disease
Auteurs : Dominique Caparros-Lefebvre ; Annie Lannuzel ; François Tiberghien ; Michel StrobelSource :
- Movement Disorders [ 0885-3185 ] ; 1999-05.
Url:
DOI: 10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S
Links to Exploration step
ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
<author><name sortKey="Caparros Efebvre, Dominique" sort="Caparros Efebvre, Dominique" uniqKey="Caparros Efebvre D" first="Dominique" last="Caparros-Lefebvre">Dominique Caparros-Lefebvre</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lannuzel, Annie" sort="Lannuzel, Annie" uniqKey="Lannuzel A" first="Annie" last="Lannuzel">Annie Lannuzel</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tiberghien, Francois" sort="Tiberghien, Francois" uniqKey="Tiberghien F" first="François" last="Tiberghien">François Tiberghien</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Strobel, Michel" sort="Strobel, Michel" uniqKey="Strobel M" first="Michel" last="Strobel">Michel Strobel</name>
<affiliation><mods:affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno>
<idno type="url">https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A06</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
<author><name sortKey="Caparros Efebvre, Dominique" sort="Caparros Efebvre, Dominique" uniqKey="Caparros Efebvre D" first="Dominique" last="Caparros-Lefebvre">Dominique Caparros-Lefebvre</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lannuzel, Annie" sort="Lannuzel, Annie" uniqKey="Lannuzel A" first="Annie" last="Lannuzel">Annie Lannuzel</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tiberghien, Francois" sort="Tiberghien, Francois" uniqKey="Tiberghien F" first="François" last="Tiberghien">François Tiberghien</name>
<affiliation><mods:affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Strobel, Michel" sort="Strobel, Michel" uniqKey="Strobel M" first="Michel" last="Strobel">Michel Strobel</name>
<affiliation><mods:affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-05">1999-05</date>
<biblScope unit="volume">14</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="535">535</biblScope>
<biblScope unit="page" to="536">536</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno>
<idno type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno>
<idno type="ArticleID">MDS1034</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Dominique Caparros‐Lefebvre MD, PhD</name>
<affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string>
</affiliations>
</json:item>
<json:item><name>Annie Lannuzel MD, PhD</name>
<affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string>
</affiliations>
</json:item>
<json:item><name>François Tiberghien MD</name>
<affiliations><json:string>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string>
</affiliations>
</json:item>
<json:item><name>Michel Strobel MD</name>
<affiliations><json:string>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</json:string>
</affiliations>
</json:item>
</author>
<articleId><json:string>MDS1034</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>letter</json:string>
</originalGenre>
<qualityIndicators><score>5.012</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>0</abstractCharCount>
<pdfWordCount>5523</pdfWordCount>
<pdfCharCount>35038</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>1</abstractWordCount>
</qualityIndicators>
<title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
<refBibs><json:item><author><json:item><name>T Lee</name>
</json:item>
<json:item><name>P Seeman</name>
</json:item>
<json:item><name>A Rajput</name>
</json:item>
<json:item><name>IJ Farley</name>
</json:item>
<json:item><name>O Horniekiewicz</name>
</json:item>
</author>
<host><volume>273</volume>
<pages><last>71</last>
<first>59</first>
</pages>
<author></author>
<title>Nature</title>
</host>
<title>Receptor basis for dopaminergic supersensitivity in Parkinson's disease</title>
</json:item>
<json:item><author><json:item><name>D Caparros‐Lefebvre</name>
</json:item>
</author>
<host><volume>73</volume>
<pages><last>944</last>
<first>938</first>
</pages>
<author></author>
<title>Sem Hôp Paris</title>
</host>
<title>Maladie de Parkinson: un traitement médical ou chirurgical adapté à la forme clinique</title>
</json:item>
<json:item><author><json:item><name>P Martinez‐Martin</name>
</json:item>
<json:item><name>CF O'Brien</name>
</json:item>
</author>
<host><volume>50</volume>
<pages><last>32</last>
<first>27</first>
</pages>
<issue>suppl 6</issue>
<author></author>
<title>Neurology</title>
</host>
<title>Extending levodopa action: COMT inhibition</title>
</json:item>
<json:item><author><json:item><name>VA Eagling</name>
</json:item>
<json:item><name>DJ Back</name>
</json:item>
<json:item><name>MG Barry</name>
</json:item>
</author>
<host><volume>44</volume>
<pages><last>194</last>
<first>190</first>
</pages>
<author></author>
<title>Br J Clin Pharmacol</title>
</host>
<title>Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir</title>
</json:item>
<json:item><author><json:item><name>MR Anari</name>
</json:item>
<json:item><name>S Khan</name>
</json:item>
<json:item><name>SD Jatoe</name>
</json:item>
<json:item><name>PJ O'Brien</name>
</json:item>
</author>
<host><volume>22</volume>
<pages><last>310</last>
<first>305</first>
</pages>
<author></author>
<title>Eur J Drug Metab</title>
</host>
<title>Cytochrome P450 dependent xenobiotic activation by physiological hydroperoxides in intact hepatocytes</title>
</json:item>
<json:item><author><json:item><name>LL Von Moltke</name>
</json:item>
<json:item><name>DJ Greenblatt</name>
</json:item>
<json:item><name>JM Grassi</name>
</json:item>
</author>
<host><volume>38</volume>
<pages><last>111</last>
<first>106</first>
</pages>
<author></author>
<title>J Clin Pharmacol</title>
</host>
<title>Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir</title>
</json:item>
</refBibs>
<genre><json:string>review-article</json:string>
</genre>
<host><volume>14</volume>
<publisherId><json:string>MDS</json:string>
</publisherId>
<pages><total>1</total>
<last>536</last>
<first>535</first>
</pages>
<issn><json:string>0885-3185</json:string>
</issn>
<issue>3</issue>
<subject><json:item><value>Letter to the Editor</value>
</json:item>
</subject>
<genre><json:string>journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<eissn><json:string>1531-8257</json:string>
</eissn>
<title>Movement Disorders</title>
<doi><json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<categories><wos><json:string>science</json:string>
<json:string>clinical neurology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>neurology & neurosurgery</json:string>
</scienceMetrix>
</categories>
<publicationDate>1999</publicationDate>
<copyrightDate>1999</copyrightDate>
<doi><json:string>10.1002/1531-8257(199905)14:3>535::AID-MDS1034>3.0.CO;2-S</json:string>
</doi>
<id>6BE0936FF1E50724857D55600AC1EC6AB4925B0D</id>
<score>0.16611259</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<availability><p>Copyright © 1999 Movement Disorder Society</p>
</availability>
<date>1999</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
<author xml:id="author-1"><persName><forename type="first">Dominique</forename>
<surname>Caparros‐Lefebvre</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
</author>
<author xml:id="author-2"><persName><forename type="first">Annie</forename>
<surname>Lannuzel</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
</author>
<author xml:id="author-3"><persName><forename type="first">François</forename>
<surname>Tiberghien</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
</author>
<author xml:id="author-4"><persName><forename type="first">Michel</forename>
<surname>Strobel</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
</author>
</analytic>
<monogr><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-05"></date>
<biblScope unit="volume">14</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="535">535</biblScope>
<biblScope unit="page" to="536">536</biblScope>
</imprint>
</monogr>
<idno type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</idno>
<idno type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</idno>
<idno type="ArticleID">MDS1034</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1999</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<textClass><keywords scheme="Journal Subject"><list><head>article-category</head>
<item><term>Letter to the Editor</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="1999-05">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/6BE0936FF1E50724857D55600AC1EC6AB4925B0D/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName>
<publisherLoc>New York</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup><id type="product" value="MDS"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="subtitle">Official Journal of the Movement Disorder Society</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/1531-8257(199905)14:3<>1.0.CO;2-I</doi>
<numberingGroup><numbering type="journalVolume" number="14">14</numbering>
<numbering type="journalIssue">3</numbering>
</numberingGroup>
<coverDate startDate="1999-05">May 1999</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="letter" position="34" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</doi>
<idGroup><id type="unit" value="MDS1034"></id>
</idGroup>
<countGroup><count type="pageTotal" number="1"></count>
</countGroup>
<titleGroup><title type="articleCategory">Letter to the Editor</title>
<title type="tocHeading1">Letters to the Editor</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright>
<eventGroup><event type="firstOnline" date="2001-01-23"></event>
<event type="publishedOnlineFinalForm" date="2001-01-23"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">535</numbering>
<numbering type="pageLast">536</numbering>
</numberingGroup>
<linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1034.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="0"></count>
<count type="referenceTotal" number="6"></count>
<count type="wordTotal" number="1081"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
<title type="short" xml:lang="en">Letters to the Editor</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Dominique</givenNames>
<familyName>Caparros‐Lefebvre</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Annie</givenNames>
<familyName>Lannuzel</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>François</givenNames>
<familyName>Tiberghien</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Michel</givenNames>
<familyName>Strobel</familyName>
<degrees>MD</degrees>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</unparsedAffiliation>
</affiliation>
</affiliationGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Letters to the Editor</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Protease inhibitors enhance levodopa effects in Parkinson's disease</title>
</titleInfo>
<name type="personal"><namePart type="given">Dominique</namePart>
<namePart type="family">Caparros‐Lefebvre</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Annie</namePart>
<namePart type="family">Lannuzel</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">François</namePart>
<namePart type="family">Tiberghien</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Neurology, Centre Hospitalier Universitaire (CHU) des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Michel</namePart>
<namePart type="family">Strobel</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Infectious Diseases, CHU des Antilles et de la Guyane, Pointe à Pitre, Guadeloupe, French West Indies, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="letter"></genre>
<originInfo><publisher>John Wiley & Sons, Inc.</publisher>
<place><placeTerm type="text">New York</placeTerm>
</place>
<dateIssued encoding="w3cdtf">1999-05</dateIssued>
<copyrightDate encoding="w3cdtf">1999</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="references">6</extent>
<extent unit="words">1081</extent>
</physicalDescription>
<relatedItem type="host"><titleInfo><title>Movement Disorders</title>
<subTitle>Official Journal of the Movement Disorder Society</subTitle>
</titleInfo>
<titleInfo type="abbreviated"><title>Mov. Disord.</title>
</titleInfo>
<genre type="journal">journal</genre>
<subject><genre>article-category</genre>
<topic>Letter to the Editor</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>14</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>3</number>
</detail>
<extent unit="pages"><start>535</start>
<end>536</end>
<total>1</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">6BE0936FF1E50724857D55600AC1EC6AB4925B0D</identifier>
<identifier type="DOI">10.1002/1531-8257(199905)14:3<535::AID-MDS1034>3.0.CO;2-S</identifier>
<identifier type="ArticleID">MDS1034</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition>
<recordInfo><recordContentSource>WILEY</recordContentSource>
<recordOrigin>John Wiley & Sons, Inc.</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:6BE0936FF1E50724857D55600AC1EC6AB4925B0D |texte= Protease inhibitors enhance levodopa effects in Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |